ArticleCureus2025
Allele-Selective Genome Editing of the Human Leukocyte Antigen Locus in Human Dental Pulp Cells Using Zinc Finger Nucleases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human dental pulp cells (DPCs) hold promise for cell-based therapies, but their allogeneic use is limited by human leukocyte antigen (HLA) incompatibility. Utilizing HLA haplotype-homozygous (HHH) donors can improve compatibility, yet sourcing donors for diverse haplotypes remains challenging. Generating pseudo-HHH cells by disrupting a specific HLA allele via gene editing offers a potential solution. This study aimed to establish zinc finger nuclease (ZFN)-mediated gene editing for allele-specific disruption of HLA-A in DPCs. We designed ZFNs to target the HLA-A*02:01 allele in DP144 DPCs (HLA-A*02:01/A*33:03, homozygous at HLA-B, -C, -DR). Following ZFN transfection and fluorescence-activated cell sorting (FACS)-mediated cell enrichment, allele-specific modifications were assessed using targeted deep sequencing, whole-genome sequencing (WGS) for off-target analysis including structural variants (SVs), and next-generation sequencing (NGS)-based HLA typing. Results demonstrated efficient (>96% indels) and specific disruption of the targeted HLA-A*02:01 allele, with minimal modification of the HLA-A*33:03 allele. Whole-genome sequencing revealed overall genomic stability, although two minor deletion-type SVs were detected in non-coding regions. Importantly, NGS HLA typing confirmed the integrity of the non-targeted HLA-A allele and other key HLA loci. These findings demonstrate the feasibility of using ZFNs to generate pseudo-HHH DPCs by allele-specific HLA knockout, providing a potential strategy to expand the donor pool for DPC-based therapies. However, careful assessment of genomic integrity is crucial for future clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.